Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated RT + Adebrelimab in Limited-Stage SCLC
NCT06527898Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-free Survival at 2 years. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06527898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527898.